Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a molecularly diverse hematologic malignancy characterized by uncontrolled proliferation and blocked differentiation of myeloid precursors.
• Despite advances, over 50% of AML patients experience relapse or refractory disease after initial treatment, highlighting the need for more effective therapies.
• Allogeneic hematopoietic stem cell transplant (HCT) offers the best curative potential for eligible AML patients.

Purpose of the Study:

• To review the current landscape of AML treatment, focusing on novel therapeutic strategies.
• To discuss the role of emerging targeted therapies and immunotherapies in improving outcomes for AML patients.
• To highlight the importance of bridging therapies to facilitate hematopoietic stem cell transplant (HCT).

Main Methods:

• Review of recent clinical trials and scientific literature on novel AML therapies.
• Analysis of targeted agents including BCL2, FLT3, IDH1/2, and menin inhibitors.
• Evaluation of emerging immunotherapeutic approaches such as CAR-T, bispecific, and trispecific antibodies.

Main Results:

• Novel targeted therapies (BCL2, FLT3, IDH1/2, menin inhibitors) demonstrate efficacy and improved tolerability, enabling better bridging to HCT.
• Targeted therapies have shown early success in managing AML, but generalized and broadly efficacious approaches are still required.
• Various targeted immunotherapeutic agents are under active investigation, showing promise for future AML treatment paradigms.

Conclusions:

• Advances in targeted therapies and immunotherapies are transforming AML treatment strategies.
• These novel agents improve patient outcomes by providing effective disease control and facilitating HCT.
• Continued research into generalized and targeted immunotherapies is crucial for overcoming challenges in AML management.